Julie Rubinstein, the President and Chief Operating Officer of Adaptive Biotechnologies Corp, has reported several transactions involving the company's stock. These transactions, which include both the acquisition and sale of shares, were disclosed in a recent SEC filing. The activity is noteworthy as it reflects Rubinstein's ongoing engagement with the company's stock and could be interpreted as a sign of confidence in the company's future prospects.

Adaptive Biotechnologies, based in Seattle, Washington, is a leader in the life sciences sector, specifically focusing on biological products that do not include diagnostic substances. The company operates under the ticker symbol ADPT and was previously known as Adaptive TCR Corp before its name change in December 2009. The company has recently filed several forms with the SEC, including multiple Form 4 submissions, which detail changes in beneficial ownership of its securities.

What the Filing Says

The latest filing, accession number 0001780664-26-000047, details multiple transactions by Rubinstein. On October 27, 2026, she acquired 11,881 shares of common stock at a price of $12.14 per share. The following day, she sold 3,000 shares at an average price of $26.58, and 8,881 shares at an average price of $27.53. Further transactions on October 28 included the acquisition of another 11,881 shares at $12.14 and the sale of 11,681 shares at an average price of $28.44.

On October 29, Rubinstein again acquired 11,881 shares at $12.14, while also selling 11,881 shares at an average price of $28.27. Following these transactions, her total ownership of Adaptive Biotechnologies shares stands at 377,802 shares.

Impact

Rubinstein's stock transactions may impact various stakeholders, including investors and analysts who monitor insider trading as a gauge of company health and future performance. The life sciences sector, particularly companies involved in biological products, will likely keep a close eye on such insider activities as they may influence market perceptions and investor sentiment.

What's Next

The filing does not indicate what happens next regarding these transactions or any future plans from Rubinstein or Adaptive Biotechnologies.